References
- Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. Arch Dermatol. 2002;138:657–63.
- Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. Alefacept Clinical Study Group. An international, randomized, double-blind, placebo controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719–27.
- Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–13.
- Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.
- Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross JB, Stewart WD, Geiger JM. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multi center study. J Am Acad Dermatol. 1991;24:598–602.
- Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989; 69:35–40.
- Hofer A, Fink-Puches R, Kerl H, Wolf P. Comparison of phototherapy with near vs. far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis. Br J Dermatol. 1998;138:96–100.
- De Jong EM, Mork NJ, Seijger MM, De La Brassine M, Lauharanta J, Jansen CT, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo controlled randomized trial. Br J Dermatol. 2003; 148:318–25.
- Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double-blind placebo study in severe psoriasis. Eur J Dermatol. 1993;3:351–4.
- Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol. 1998; 139:88–95.
- Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo controlled trial. J Am Acad Dermatol. 2004;51(4):534–42.
- Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41:51–9.
- Maughan WZ, Muller SA, Perry HO, Pittelkow MR, O’Brien PC. Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. J Am Acad Dermatol. 1980;3:612–15.
- Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O’Brien PC. Skin cancer in patients with psoriasis treated with coal tar: a 25-year follow-up study. Arch Dermatol. 1981;117:465–8.
- National Psoriasis Foundation Forum.Winter 2002. p 3.
- Hannuksela-Svahn A, Pukkala E, Koulu L, Jansen CT, Karvonen J. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol. 1999;40:694–6.
- Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, Young M, McClelland P. Consensus con ference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001; 45:544–53.